GetTopicDetailResponse(id=d05e12666846, topicName=HH2853, introduction=, content=外周T細胞淋巴瘤 HH2853, image=null, comments=0, allHits=251, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Tue May 06 22:08:06 CST 2025, time=2025-05-06, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=504241, tagList=[TagDto(tagId=504241, tagName=HH2853)], ipAttribution=陜西省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2271632, encodeId=92c422e16325e, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T細胞淋巴瘤#</a> <a href='/topic/show?id=d05e12666846' target=_blank style='color:#2F92EE;'>#HH2853#</a>, objectTitle=JHO：新型EZH1/2雙重抑制劑在復發(fā)難治性外周T細胞淋巴瘤中的安全性及療效觀察, objectType=article, longId=885020, objectId=e7b388502052, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PTE4SCK.jpg, objectUrl=/article/show_article.do?id=e7b388502052, replyNumber=0, likeNumber=25, createdTime=2025-07-01, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e7b388502052, moduleTitle=JHO：新型EZH1/2雙重抑制劑在復發(fā)難治性外周T細胞淋巴瘤中的安全性及療效觀察, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e7b388502052)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2263753, encodeId=588a2263e53d0, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T細胞淋巴瘤#</a> <a href='/topic/show?id=d05e12666846' target=_blank style='color:#2F92EE;'>#HH2853#</a>, objectTitle=中國多中心Ib期研究證實EZH1/2抑制劑HH2853治療r/r PTCL安全有效, objectType=article, longId=874919, objectId=94848e49193d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220801/1659342224826_8252897.webp, objectUrl=/article/show_article.do?id=94848e49193d, replyNumber=0, likeNumber=44, createdTime=2025-05-06, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=94848e49193d, moduleTitle=中國多中心Ib期研究證實EZH1/2抑制劑HH2853治療r/r PTCL安全有效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=94848e49193d)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-05-06發(fā)表于陜西省
